These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37278948)

  • 1. Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.
    Kesavadev J; Basanth A; Krishnan G; Shankar A; Sanal G; Jothydev S
    Diabetes Ther; 2023 Aug; 14(8):1319-1330. PubMed ID: 37278948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users.
    Elbarbary NS; Ismail EAR
    Diabetol Metab Syndr; 2023 Oct; 15(1):205. PubMed ID: 37845757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users.
    Silva JD; Lepore G; Battelino T; Arrieta A; Castañeda J; Grossman B; Shin J; Cohen O
    Diabetes Technol Ther; 2022 Feb; 24(2):113-119. PubMed ID: 34524003
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
    Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
    Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Glycemic Outcomes During the MiniMed
    Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
    Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
    Arunachalum S; Velado K; Vigersky RA; Cordero TL
    J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed‑loop system: A randomized controlled trial.
    Elbarbary NS; Ismail EAR
    Diabetes Res Clin Pract; 2022 Sep; 191():110045. PubMed ID: 35987309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
    Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
    Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
    Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience.
    Halim B; Abraham MB; Manos G; Arrieta A; Dai Z; Vogrin S; Lu J; MacIsaac R; Ekinci EI; Davis EA; Jenkins A; Shin J; Vigersky RA; Jones TW; O'Neal D
    Diabetes Technol Ther; 2024 Mar; 26(3):190-197. PubMed ID: 38444313
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
    Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
    Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world performance of the MiniMed™ 670G system in Europe.
    Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
    Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence.
    Choudhary P; Arrieta A; van den Heuvel T; Castañeda J; Smaniotto V; Cohen O
    Diabetes Technol Ther; 2024 Mar; 26(S3):32-37. PubMed ID: 38377326
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
    Grassi B; Gómez AM; Calliari LE; Franco D; Raggio M; Riera F; Castro M; McVean J; van den Heuvel T; Arrieta A; Castañeda J; Cohen O
    Diabetes Obes Metab; 2023 Jun; 25(6):1688-1697. PubMed ID: 36789699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort.
    Matejko B; van den Heuvel T; Castaneda J; Arrieta A; Cyranka K; Cohen O; Małecki M; Klupa T
    Diabetes Res Clin Pract; 2024 Oct; 216():111832. PubMed ID: 39173678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus.
    Pei Y; Ke W; Lu J; Lin Y; Zhang Z; Peng Y; Bi Y; Li Y; Hou J; Zhang X; Chen X; Treminio Y; Lee SW; Shin J; Rhinehart AS; Vigersky RA; Mu Y
    Diabetes Technol Ther; 2023 Oct; 25(10):718-725. PubMed ID: 37578804
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial.
    Forlenza GP; Ekhlaspour L; DiMeglio LA; Fox LA; Rodriguez H; Shulman DI; Kaiserman KB; Liljenquist DR; Shin J; Lee SW; Buckingham BA
    Pediatr Diabetes; 2022 May; 23(3):324-329. PubMed ID: 35001477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.